Feb. 28, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie's upadacitinib (Rinvoq) to treat adults with giant cell arteritis (GCA).

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...

AbbVie said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults ...

Samsung’s Project Moohan XR headset might have been on show at MWC 2025, but Samsung didn’t actually give us any information on what to expect from the device. However a new report from The ...

Use cases for AI in extended reality (XR) applications are truly limitless. AI can support visualisations of natural phenomena by pre-processing data. For example, a research team from the ...

AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price just a little below that of its antibody blockbuster Humira.

The EU regulator has cleared Rinvoq (upadacitinib) as an oral treatment for moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older, either with or without topical ...

Samsung’s upcoming Android XR project is turning heads, not just because it has a variety of Vision Pro-like features, but because it may have even better displays than Apple’s $3,500 headset.